Astrana Health (NASDAQ:ASTH) Sets New 1-Year Low After Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price hit a new 52-week low during mid-day trading on Monday after Truist Financial lowered their price target on the stock from $59.00 to $50.00. Truist Financial currently has a buy rating on the stock. Astrana Health traded as low as $29.08 and last traded at $29.42, with a volume of 13470 shares trading hands. The stock had previously closed at $29.48.

Other equities analysts have also recently issued reports about the company. KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating for the company. Macquarie upgraded Astrana Health to a “hold” rating in a report on Monday, December 16th. BTIG Research increased their target price on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, TD Cowen started coverage on Astrana Health in a research report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $63.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $35,000. KBC Group NV purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $70,000. Quarry LP purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $77,000. Finally, Quest Partners LLC purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $133,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $1.65 billion, a PE ratio of 22.63, a P/E/G ratio of 1.80 and a beta of 1.20. The stock has a 50 day moving average of $39.55 and a two-hundred day moving average of $47.00.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the firm posted $0.47 earnings per share. Research analysts expect that Astrana Health, Inc. will post 1.16 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.